|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02500 VENUS MEDTECH-B
Nominal 
5.620 0.000 (0.000%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 491,373 | 20.891% | 406,461 | 415,862 | 276,047 | 233,272 |
| Cost of Sales | (102,168) | 10.496% | (92,463) | (91,518) | (48,767) | (38,607) |
| Gross Profit | 389,205 | 23.951% | 313,998 | 324,344 | 227,280 | 194,665 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 2,210 | -- | (21,972) | (3,185) | 50 | (2,172) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (12,381) | -11.203% | (13,943) | (11,711) | 570 | 0 | |
| Profit / (Loss) before Taxation | (735,340) | -36.408% | (1,156,344) | (377,555) | (185,843) | (381,543) | |
| Taxation | 6,284 | -81.680% | 34,302 | 6,161 | 2,975 | 778 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 25,302 | -60.676% | 64,343 | (2,242) | 879 | 42 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (703,754) | -33.464% | (1,057,699) | (373,636) | (181,989) | (380,723) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 28,259 | 183.298% | 9,975 | (47,575) | (30,495) | 15,757 |
| Depreciation & Amortisation | 124,787 | 11.068% | 112,352 | 51,621 | 37,712 | 28,906 |
| Directors' Emoluments | 3,905 | -13.968% | 4,539 | 4,478 | 3,841 | 29,325 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -165.000 | -31.818% | -242.000 | -85.000 | -45.000 | -122.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (1.393) | -- | (1.666) | (1.042) | (0.579) | (0.975) |
| NBV per share ($) | 6.623 | -- | 8.181 | 10.307 | 9.021 | 7.509 |
| Remarks: | Real time quote last updated: 11/11/2024 09:44 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -206,487,000 |
| %Change | -41.035% |
| EPS / (LPS) | RMB -0.470 |
| NBV Per Share (¥) | RMB 6.180 |